How should I diagnose and manage an adult with suspected COVID-19, including isolation, antiviral selection for high-risk patients, and treatment of moderate to severe disease?

COVID-19 Diagnosis and Management in Adults

For high-risk adults with confirmed mild-to-moderate COVID-19 within 5 days of symptom onset, use nirmatrelvir-ritonavir as first-line antiviral therapy, with molnupiravir as an alternative when nirmatrelvir-ritonavir is contraindicated or unavailable. 1, 2, 3

Diagnosis

Testing Strategy

• Test all symptomatic individuals suspected of COVID-19 using nucleic acid amplification tests (NAAT) 4
• Test asymptomatic individuals with known or suspected COVID-19 exposure 4
• Consider testing asymptomatic individuals without known exposure when results will impact:
  • Isolation/quarantine decisions
  • PPE usage
  • Surgical eligibility
  • Immunosuppressive therapy administration 4

Diagnostic Methods Available

• Clinical presentation assessment
• Rapid antigen/antibody testing
• Molecular testing (NAAT - gold standard)
• Supplemental laboratory analysis
• Imaging studies 5

Isolation and Cohorting

Implement risk-stratified triage to protect high-risk patients from hospital-acquired COVID-19 6:

Triage Categories (Priority Order for Single-Room Isolation)

1. Category A (HIGHEST PRIORITY): Low COVID-19 likelihood + High risk for severe disease
2. Category B: High COVID-19 likelihood + High risk for severe disease
3. Category C: High COVID-19 likelihood + Low risk for severe disease
4. Category D: Low COVID-19 likelihood + Low risk for severe disease

Cohort low-risk patients (Categories C and D) when isolation capacity is limited - this strategy has demonstrated no symptomatic hospital-acquired infections in cohorted patients 6

Antiviral Treatment for Mild-to-Moderate Disease

Patient Selection Criteria

Treat symptomatic patients with all of the following:

• Confirmed COVID-19 diagnosis
• Mild-to-moderate disease severity
• Within 5 days of symptom onset (critical timing window)
• High risk for progression to severe disease 1, 2, 3

High-Risk Factors Include

• Advanced age
• Chronic obstructive pulmonary disease
• Heart disease
• Diabetes
• Chronic kidney disease
• Obesity
• Immunocompromised status 5

Antiviral Selection Algorithm

First-Line: Nirmatrelvir-Ritonavir

• Reduces all-cause mortality (4 studies showing reduction) 1
• Reduces COVID-19 mortality 1
• Reduces hospital admissions 1
• Reduces time to recovery 1
• No difference in adverse events compared to no treatment 1
• Most recent guidelines (2026) reaffirm this as preferred agent 2, 3

Second-Line: Molnupiravir

• Use when nirmatrelvir-ritonavir is contraindicated or unavailable 1, 3
• Reduces all-cause mortality (3 studies showing reduction) 1
• Reduces time to recovery 1
• No difference in adverse events 1

Critical Timing

Both antivirals must be initiated within 5 days of symptom onset to achieve mortality and hospitalization benefits 1, 2, 3

Treatments to AVOID

Do NOT use the following in outpatient COVID-19:

• Ivermectin - no clinical benefit demonstrated 1, 3
• Sotrovimab - not supported by evidence 1, 3
• Hydroxychloroquine (with or without azithromycin) - no reduction in viral load or symptom severity, but increased mortality in hospitalized patients; FDA authorization revoked 5

Moderate-to-Severe/Critical Disease Management

Corticosteroids

Dexamethasone is the established corticosteroid for critically ill COVID-19 patients:

• Reduces inflammation and prevents respiratory failure
• Demonstrated mortality benefit in RECOVERY trial 5

Important caveats with corticosteroid use:

• Risk of hyperglycemia
• Immunosuppression
• Delayed viral clearance
• Requires careful administration and monitoring 5

Immunomodulatory Agents Under Investigation

For severe inflammatory response/cytokine release syndrome:

• Tocilizumab, sarilumab (IL-6 inhibitors)
• Baricitinib, ruxolitinib (JAK inhibitors)
• Colchicine
• Other monoclonal antibodies (itolizumab, gimsilumab) 5

Antiviral for Hospitalized Patients

Remdesivir (adenosine nucleotide analog):

• Inhibits viral RNA polymerase
• FDA emergency use authorization for hospitalized patients
• Shown to reduce COVID-19 severity 5

Common Pitfalls to Avoid

1. Missing the 5-day treatment window - antivirals lose effectiveness after this critical period
2. Failing to risk-stratify patients - high-risk patients require priority isolation and antiviral treatment
3. Using ineffective therapies - avoid ivermectin, hydroxychloroquine, and sotrovimab despite early pandemic use
4. Delaying testing in symptomatic patients - early diagnosis enables timely antiviral initiation
5. Inappropriate corticosteroid use - reserve for critically ill patients; risks outweigh benefits in mild disease

Evidence Quality Note

The 2024 American College of Physicians guidelines 1 and 2026 IDSA guidelines 2 represent the highest quality, most recent evidence. New studies from 2023 showed reductions in mortality with both nirmatrelvir-ritonavir and molnupiravir, but were deemed "unlikely" to change existing practice points, confirming the robustness of current recommendations 1. The ACP has retired this topic from living guideline status given the stability of recommendations 3.